Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Arcadia Medicine

3 Drug Candidates

Arcadia Medicine is a San Francisco-based biotech developing safe entactogens for mental health disorders. Their lead candidate AM-1002 is a patented non-racemic MDMA formulation that received FDA IND clearance in October 2025 for Phase 1 trials in generalized anxiety disorder. Backed by investors including Sam Altman and Coinbase co-founder Fred Ehrsam.

Drug Pipeline

3

AM-1002

MDMA
Phase I
Anxiety DisordersMajor Depressive Disorder (MDD)

Non-racemic, non-neurotoxic MDMA formulation with shorter time course. FDA IND cleared Oct 2025. Phase 1 for GAD.

AM-1004

MDMA
Pre-clinical
Major Depressive Disorder (MDD)

Mildly entactogenic antidepressant designed for self-administration as SSRI/SNRI alternative.

AM-1006

Pre-clinical
Substance Use Disorders (SUD)

Short-acting, subperceptual psychoactive for traditional hour-long therapy sessions.

Quick Facts

Type
Private Biotech
Lead Stage
Phase I
Website
Visit